Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Novel method could improve treatment for infants, young children suffering from HIV/AIDS

Novel method could improve treatment for infants, young children suffering from HIV/AIDS

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda